Feb 7, 2018 Syros Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
Jan 22, 2018 Syros Announces Issuance of U.S. Patents Covering Methods for Stratifying Patients for Treatment with SY-1425, Its First-in-Class Selective RARĪ± Agonist
Jan 8, 2018 Incyte and Syros Announce Global Target Discovery and Validation Collaboration Focused on Myeloproliferative Neoplasms
Jan 2, 2018 Syros Announces Clinical Supply Agreement with Janssen to Evaluate SY-1425, Its First-in-Class Selective RARĪ± Agonist, in Combination with Daratumumab in Genomically Defined AML and MDS Patients
Dec 10, 2017 Syros Announces Initial Clinical Data from Ongoing Phase 2 Trial of SY-1425 Showing Biological and Clinical Activity as Single Agent in Genomically Defined AML and MDS Patients
Dec 10, 2017 Syros Announces New Preclinical Data on SY-1365, Its First-in-Class Selective CDK7 Inhibitor, Pointing to a Potential Biomarker of Response and Combination Approach
